Rheumatoid Arthritis — Deal Benchmarks & Valuation
Market Analysis
Rheumatoid Arthritis is one of the most actively transacted indications in immunology licensing. Phase 2 deals for rheumatoid arthritis carry a median total deal value of $2.5B, with upfront payments ranging from $255M to $695M. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones.
Milestone structures for rheumatoid arthritis deals allocate $405M to development milestones, $708M to regulatory milestones, and $911M to commercial milestones. Royalty rates range from 13.2% to 22.1% at the base tier, with tiered escalation reaching 17.2%-26.1% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for rheumatoid arthritis licensing?
What royalty rates are standard for rheumatoid arthritis deals?
How are rheumatoid arthritis deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.